BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
Kubo T, Kawano Y, Himuro N, Sugita S, Sato Y, Ishikawa K, Takada K, Murase K, Miyanishi K, Sato T, Takimoto R, Kobune M, Nobuoka T, Hirata K, Takayama T, Mori M, Hasegawa T, Kato J.
Kubo T, et al.
Gastric Cancer. 2016 Jul;19(3):827-38. doi: 10.1007/s10120-015-0557-1. Epub 2015 Oct 20.
Gastric Cancer. 2016.
PMID: 26486506
Clinical Trial.